AustralieFrV1, PascalFrancis, Curation, bibRecord, 006E54

Efficacy and safety of an oral fixed low-dose perindopril 2 mg/indapamide 0.625 mg combination : A randomized, double-blind, placebo-controlled study in elderly patients with mild to moderate hypertension

Identifieur interne : 006E54 ( PascalFrancis/Curation ); précédent : 006E53; suivant : 006E55

Efficacy and safety of an oral fixed low-dose perindopril 2 mg/indapamide 0.625 mg combination : A randomized, double-blind, placebo-controlled study in elderly patients with mild to moderate hypertension

Auteurs : A. Castaigne [France] ; J. Chalmers [Australie] ; T. Morgan [Australie] ; C. Chastang [France] ; L. Feldmann [France] ; D. Guez [France]

Source :

Clinical and experimental hypertension : (1993) [ 1064-1963 ] ; 1999.

RBID : Pascal:99-0516720

Descripteurs français

Pascal (Inist)
- Hypertension artérielle, Voie orale, Antihypertenseur, Périndopril, Inhibiteur angiotensin converting enzyme, Indapamide, Diurétique, Dose faible, Traitement, Chimiothérapie, Association médicamenteuse, Homme.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- ACE inhibitor, Antihypertensive agent, Chemotherapy, Diuretic, Drug combination, Human, Hypertension, Indapamide, Low dose, Oral administration, Perindopril, Treatment.

Abstract

The efficacy and safety of 12 weeks treatment with an oral fixed low-dose perindopril 2 mg + indapamide 0.625 mg (Per/Ind) combination in elderly and very elderly patients (65-85 years) with mild to moderate systolic and diastolic hypertension (SDH) or isolated systolic hypertension (ISH) were investigated vs placebo. This trial was a multinational randomized double-blind study with doubling of active drug dosage in nonresponders. Intention to treat analysis was performed in 383 patients (age 72.4 years ; ISH 32%). 58.5% remained on their initial dosage. Per/Ind decreased supine diastolic and systolic blood pressure (sDBP/sSBP) by 13.2 ± 8.0 mm Hg and 22.5 ± 13.9 mm Hg (P <.0001) versus placebo - 7.3 ± 9.0 mm Hg and - 12.3 ± 15.2 mm Hg, respectively. In ISH (n = 123), Per/Ind decreased sSBP by 23.0 ± 11.8 mm Hg (P <.0001). Overall response and normotension rates was 81.3% with Per/Ind (P <.0001). Adverse event rates (including hypokalemia) were similarly low in both groups. Analysis in the over-75 year subgroup showed similar safety and efficacy results. Fixed low-dose Per/Ind is a safe and effective treatment of hypertension including isolated systolic hypertension in the elderly.

A01	`01`	`1`		`@0 1064-1963`
A03		`1`		`@0 Clin. exp. hypertens. : (1993)`
A05				`@2 21`
A06				`@2 7`
A08	`01`	`1`	`ENG`	`@1 Efficacy and safety of an oral fixed low-dose perindopril 2 mg/indapamide 0.625 mg combination : A randomized, double-blind, placebo-controlled study in elderly patients with mild to moderate hypertension`
A11	`01`	`1`		`@1 CASTAIGNE (A.)`
A11	`02`	`1`		`@1 CHALMERS (J.)`
A11	`03`	`1`		`@1 MORGAN (T.)`
A11	`04`	`1`		`@1 CHASTANG (C.)`
A11	`05`	`1`		`@1 FELDMANN (L.)`
A11	`06`	`1`		`@1 GUEZ (D.)`
A14	`01`			`@1 Hôpital Henri Mondor @2 Créteil @3 FRA @Z 1 aut.`
A14	`02`			`@1 Department of Medicine, Flinders Medical Center @2 Bedford Park @3 AUS @Z 2 aut.`
A14	`03`			`@1 Department of Physiology, University of Melbourne @2 Parkville, Victoria @3 AUS @Z 3 aut.`
A14	`04`			`@1 Department for Biostatistical and Medical Information, Hôpital Saint Louis @2 Paris @3 FRA @Z 4 aut.`
A14	`05`			`@1 Institut de Recherches Internationales Servier @2 Courbevoie @3 FRA @Z 5 aut. @Z 6 aut.`
A20				`@1 1097-1110`
A21				`@1 1999`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 18049A @5 354000088194510030`
A44				`@0 0000 @1 © 1999 INIST-CNRS. All rights reserved.`
A45				`@0 15 ref.`
A47	`01`	`1`		`@0 99-0516720`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Clinical and experimental hypertension : (1993)`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 The efficacy and safety of 12 weeks treatment with an oral fixed low-dose perindopril 2 mg + indapamide 0.625 mg (Per/Ind) combination in elderly and very elderly patients (65-85 years) with mild to moderate systolic and diastolic hypertension (SDH) or isolated systolic hypertension (ISH) were investigated vs placebo. This trial was a multinational randomized double-blind study with doubling of active drug dosage in nonresponders. Intention to treat analysis was performed in 383 patients (age 72.4 years ; ISH 32%). 58.5% remained on their initial dosage. Per/Ind decreased supine diastolic and systolic blood pressure (sDBP/sSBP) by 13.2 ± 8.0 mm Hg and 22.5 ± 13.9 mm Hg (P <.0001) versus placebo - 7.3 ± 9.0 mm Hg and - 12.3 ± 15.2 mm Hg, respectively. In ISH (n = 123), Per/Ind decreased sSBP by 23.0 ± 11.8 mm Hg (P <.0001). Overall response and normotension rates was 81.3% with Per/Ind (P <.0001). Adverse event rates (including hypokalemia) were similarly low in both groups. Analysis in the over-75 year subgroup showed similar safety and efficacy results. Fixed low-dose Per/Ind is a safe and effective treatment of hypertension including isolated systolic hypertension in the elderly.
C02	`01`	`X`		`@0 002B02F05`
C03	`01`	`X`	`FRE`	`@0 Hypertension artérielle @5 01`
C03	`01`	`X`	`ENG`	`@0 Hypertension @5 01`
C03	`01`	`X`	`SPA`	`@0 Hipertensión arterial @5 01`
C03	`02`	`X`	`FRE`	`@0 Voie orale @5 04`
C03	`02`	`X`	`ENG`	`@0 Oral administration @5 04`
C03	`02`	`X`	`SPA`	`@0 Vía oral @5 04`
C03	`03`	`X`	`FRE`	`@0 Antihypertenseur @5 07`
C03	`03`	`X`	`ENG`	`@0 Antihypertensive agent @5 07`
C03	`03`	`X`	`SPA`	`@0 Antihipertensivo @5 07`
C03	`04`	`X`	`FRE`	`@0 Périndopril @2 NK @2 FR @5 10`
C03	`04`	`X`	`ENG`	`@0 Perindopril @2 NK @2 FR @5 10`
C03	`04`	`X`	`SPA`	`@0 Perindopril @2 NK @2 FR @5 10`
C03	`05`	`X`	`FRE`	`@0 Inhibiteur angiotensin converting enzyme @5 11`
C03	`05`	`X`	`ENG`	`@0 ACE inhibitor @5 11`
C03	`05`	`X`	`SPA`	`@0 Inhibidor angiotensin converting enzyme @5 11`
C03	`06`	`X`	`FRE`	`@0 Indapamide @2 NK @2 FR @5 13`
C03	`06`	`X`	`ENG`	`@0 Indapamide @2 NK @2 FR @5 13`
C03	`06`	`X`	`SPA`	`@0 Indapamida @2 NK @2 FR @5 13`
C03	`07`	`X`	`FRE`	`@0 Diurétique @5 14`
C03	`07`	`X`	`ENG`	`@0 Diuretic @5 14`
C03	`07`	`X`	`SPA`	`@0 Diurético @5 14`
C03	`08`	`X`	`FRE`	`@0 Dose faible @5 16`
C03	`08`	`X`	`ENG`	`@0 Low dose @5 16`
C03	`08`	`X`	`SPA`	`@0 Dosis débil @5 16`
C03	`09`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`09`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`09`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`10`	`X`	`FRE`	`@0 Chimiothérapie @5 18`
C03	`10`	`X`	`ENG`	`@0 Chemotherapy @5 18`
C03	`10`	`X`	`SPA`	`@0 Quimioterapia @5 18`
C03	`11`	`X`	`FRE`	`@0 Association médicamenteuse @5 19`
C03	`11`	`X`	`ENG`	`@0 Drug combination @5 19`
C03	`11`	`X`	`SPA`	`@0 Asociación medicamentosa @5 19`
C03	`12`	`X`	`FRE`	`@0 Homme @5 20`
C03	`12`	`X`	`ENG`	`@0 Human @5 20`
C03	`12`	`X`	`SPA`	`@0 Hombre @5 20`
C07	`01`	`X`	`FRE`	`@0 Appareil circulatoire pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Cardiovascular disease @5 37`
C07	`01`	`X`	`SPA`	`@0 Aparato circulatorio patología @5 37`
N21				`@1 333`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :006200

Links to Exploration step

Pascal:99-0516720

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Efficacy and safety of an oral fixed low-dose perindopril 2 mg/indapamide 0.625 mg combination : A randomized, double-blind, placebo-controlled study in elderly patients with mild to moderate hypertension</title>
<author><name sortKey="Castaigne, A" sort="Castaigne, A" uniqKey="Castaigne A" first="A." last="Castaigne">A. Castaigne</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Hôpital Henri Mondor</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Chalmers, J" sort="Chalmers, J" uniqKey="Chalmers J" first="J." last="Chalmers">J. Chalmers</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Medicine, Flinders Medical Center</s1>
<s2>Bedford Park</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Morgan, T" sort="Morgan, T" uniqKey="Morgan T" first="T." last="Morgan">T. Morgan</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Physiology, University of Melbourne</s1>
<s2>Parkville, Victoria</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Chastang, C" sort="Chastang, C" uniqKey="Chastang C" first="C." last="Chastang">C. Chastang</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department for Biostatistical and Medical Information, Hôpital Saint Louis</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Feldmann, L" sort="Feldmann, L" uniqKey="Feldmann L" first="L." last="Feldmann">L. Feldmann</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Institut de Recherches Internationales Servier</s1>
<s2>Courbevoie</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Guez, D" sort="Guez, D" uniqKey="Guez D" first="D." last="Guez">D. Guez</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Institut de Recherches Internationales Servier</s1>
<s2>Courbevoie</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">99-0516720</idno>
<date when="1999">1999</date>
<idno type="stanalyst">PASCAL 99-0516720 INIST</idno>
<idno type="RBID">Pascal:99-0516720</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">006200</idno>
<idno type="wicri:Area/PascalFrancis/Curation">006E54</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Efficacy and safety of an oral fixed low-dose perindopril 2 mg/indapamide 0.625 mg combination : A randomized, double-blind, placebo-controlled study in elderly patients with mild to moderate hypertension</title>
<author><name sortKey="Castaigne, A" sort="Castaigne, A" uniqKey="Castaigne A" first="A." last="Castaigne">A. Castaigne</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Hôpital Henri Mondor</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Chalmers, J" sort="Chalmers, J" uniqKey="Chalmers J" first="J." last="Chalmers">J. Chalmers</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Medicine, Flinders Medical Center</s1>
<s2>Bedford Park</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Morgan, T" sort="Morgan, T" uniqKey="Morgan T" first="T." last="Morgan">T. Morgan</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Physiology, University of Melbourne</s1>
<s2>Parkville, Victoria</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Chastang, C" sort="Chastang, C" uniqKey="Chastang C" first="C." last="Chastang">C. Chastang</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department for Biostatistical and Medical Information, Hôpital Saint Louis</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Feldmann, L" sort="Feldmann, L" uniqKey="Feldmann L" first="L." last="Feldmann">L. Feldmann</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Institut de Recherches Internationales Servier</s1>
<s2>Courbevoie</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Guez, D" sort="Guez, D" uniqKey="Guez D" first="D." last="Guez">D. Guez</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Institut de Recherches Internationales Servier</s1>
<s2>Courbevoie</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Clinical and experimental hypertension : (1993)</title>
<title level="j" type="abbreviated">Clin. exp. hypertens. : (1993)</title>
<idno type="ISSN">1064-1963</idno>
<imprint><date when="1999">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Clinical and experimental hypertension : (1993)</title>
<title level="j" type="abbreviated">Clin. exp. hypertens. : (1993)</title>
<idno type="ISSN">1064-1963</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>ACE inhibitor</term>
<term>Antihypertensive agent</term>
<term>Chemotherapy</term>
<term>Diuretic</term>
<term>Drug combination</term>
<term>Human</term>
<term>Hypertension</term>
<term>Indapamide</term>
<term>Low dose</term>
<term>Oral administration</term>
<term>Perindopril</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Hypertension artérielle</term>
<term>Voie orale</term>
<term>Antihypertenseur</term>
<term>Périndopril</term>
<term>Inhibiteur angiotensin converting enzyme</term>
<term>Indapamide</term>
<term>Diurétique</term>
<term>Dose faible</term>
<term>Traitement</term>
<term>Chimiothérapie</term>
<term>Association médicamenteuse</term>
<term>Homme</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The efficacy and safety of 12 weeks treatment with an oral fixed low-dose perindopril 2 mg + indapamide 0.625 mg (Per/Ind) combination in elderly and very elderly patients (65-85 years) with mild to moderate systolic and diastolic  hypertension (SDH) or isolated systolic hypertension (ISH) were investigated vs placebo. This trial was a multinational randomized double-blind study with doubling of active drug dosage in nonresponders. Intention to treat analysis was performed in 383 patients (age 72.4 years ; ISH 32%). 58.5% remained on their initial dosage. Per/Ind decreased supine diastolic and systolic blood pressure (sDBP/sSBP) by 13.2 ± 8.0 mm Hg and 22.5 ± 13.9 mm Hg (P <.0001) versus placebo - 7.3 ± 9.0 mm Hg and - 12.3 ± 15.2 mm Hg, respectively. In ISH (n = 123), Per/Ind decreased sSBP by 23.0 ± 11.8 mm Hg (P <.0001). Overall response and normotension rates was 81.3% with Per/Ind (P <.0001). Adverse event rates (including hypokalemia) were similarly low in both groups. Analysis in the over-75 year subgroup showed similar safety and efficacy results. Fixed low-dose Per/Ind is a safe and effective treatment of hypertension including isolated systolic hypertension in the elderly.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1064-1963</s0>
</fA01>
<fA03 i2="1"><s0>Clin. exp. hypertens. : (1993)</s0>
</fA03>
<fA05><s2>21</s2>
</fA05>
<fA06><s2>7</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Efficacy and safety of an oral fixed low-dose perindopril 2 mg/indapamide 0.625 mg combination : A randomized, double-blind, placebo-controlled study in elderly patients with mild to moderate hypertension</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>CASTAIGNE (A.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>CHALMERS (J.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MORGAN (T.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>CHASTANG (C.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>FELDMANN (L.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>GUEZ (D.)</s1>
</fA11>
<fA14 i1="01"><s1>Hôpital Henri Mondor</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Medicine, Flinders Medical Center</s1>
<s2>Bedford Park</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Physiology, University of Melbourne</s1>
<s2>Parkville, Victoria</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department for Biostatistical and Medical Information, Hôpital Saint Louis</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Institut de Recherches Internationales Servier</s1>
<s2>Courbevoie</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>1097-1110</s1>
</fA20>
<fA21><s1>1999</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>18049A</s2>
<s5>354000088194510030</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1999 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>15 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>99-0516720</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Clinical and experimental hypertension : (1993)</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The efficacy and safety of 12 weeks treatment with an oral fixed low-dose perindopril 2 mg + indapamide 0.625 mg (Per/Ind) combination in elderly and very elderly patients (65-85 years) with mild to moderate systolic and diastolic  hypertension (SDH) or isolated systolic hypertension (ISH) were investigated vs placebo. This trial was a multinational randomized double-blind study with doubling of active drug dosage in nonresponders. Intention to treat analysis was performed in 383 patients (age 72.4 years ; ISH 32%). 58.5% remained on their initial dosage. Per/Ind decreased supine diastolic and systolic blood pressure (sDBP/sSBP) by 13.2 ± 8.0 mm Hg and 22.5 ± 13.9 mm Hg (P <.0001) versus placebo - 7.3 ± 9.0 mm Hg and - 12.3 ± 15.2 mm Hg, respectively. In ISH (n = 123), Per/Ind decreased sSBP by 23.0 ± 11.8 mm Hg (P <.0001). Overall response and normotension rates was 81.3% with Per/Ind (P <.0001). Adverse event rates (including hypokalemia) were similarly low in both groups. Analysis in the over-75 year subgroup showed similar safety and efficacy results. Fixed low-dose Per/Ind is a safe and effective treatment of hypertension including isolated systolic hypertension in the elderly.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02F05</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Hypertension artérielle</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Hypertension</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Hipertensión arterial</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Voie orale</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Oral administration</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Vía oral</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Antihypertenseur</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Antihypertensive agent</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Antihipertensivo</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Périndopril</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Perindopril</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Perindopril</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Inhibiteur angiotensin converting enzyme</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>ACE inhibitor</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Inhibidor angiotensin converting enzyme</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Indapamide</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Indapamide</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Indapamida</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Diurétique</s0>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Diuretic</s0>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Diurético</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Dose faible</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Low dose</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Dosis débil</s0>
<s5>16</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>18</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>18</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>18</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Association médicamenteuse</s0>
<s5>19</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Drug combination</s0>
<s5>19</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Asociación medicamentosa</s0>
<s5>19</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Appareil circulatoire pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cardiovascular disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0>
<s5>37</s5>
</fC07>
<fN21><s1>333</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006E54 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 006E54 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:99-0516720
   |texte=   Efficacy and safety of an oral fixed low-dose perindopril 2 mg/indapamide 0.625 mg combination : A randomized, double-blind, placebo-controlled study in elderly patients with mild to moderate hypertension
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Efficacy and safety of an oral fixed low-dose perindopril 2 mg/indapamide 0.625 mg combination : A randomized, double-blind, placebo-controlled study in elderly patients with mild to moderate hypertension

Efficacy and safety of an oral fixed low-dose perindopril 2 mg/indapamide 0.625 mg combination : A randomized, double-blind, placebo-controlled study in elderly patients with mild to moderate hypertension

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri